1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159672A
    3D-Monophosphoryl Lipid (12,16) free acid 220048-49-7 98%
    3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) free acid is a TLR agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
    3D-Monophosphoryl Lipid (12,16) free acid
  • HY-159692A
    AZD8701 sodium 98%
    AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer.
    AZD8701 sodium
  • HY-160073A
    Florensocatib hydrate 2971064-13-6 98%
    Florensocatib hydrate is a DPP1 inhibitor (IC50: 1.6 nM). Florensocatib hydrate has good bioavailability and pharmacokinetic characteristics, and can be used for research of inflammatory disease.
    Florensocatib hydrate
  • HY-160169A
    Necrosis inhibitor 2 (hydrocholide) 98%
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases.
    Necrosis inhibitor 2 (hydrocholide)
  • HY-160216A
    RIPK1-IN-18 sulfate hydrate 2897618-64-1 98%
    RIPK1-IN-18 sulfate hydrate is a potent RIPK1 inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i).
    RIPK1-IN-18 sulfate hydrate
  • HY-160228A
    ORN 02 sodium
    ORN 02 (sodium) is a synthetic single-stranded U-rich RNA and contains 6 repeats of UUAU sequence motif. The AU-rich oligoribonucleotides (ORNs) are able to stimulate TLR8.
    ORN 02 sodium
  • HY-162655A
    SLF80821178 hydrochloride 2764877-62-3 98%
    SLF80821178 hydrochloride is an orally active inhibitor for sphingosine-1-phosphate transporter (Spns2), that inhibits the sphingosine-1-phosphate (S1P) release in HeLa with an IC50 of 51 nM. SLF80821178 hydrochloride reduces the circulating lymphocyte without affecting plasma S1P levels in mice.
    SLF80821178 hydrochloride
  • HY-163312S
    Tyk2-IN-18-d5 3018160-63-6 98%
    Tyk2-IN-18-d5 (Compound 13) is the deuterated TYK2 inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases.
    Tyk2-IN-18-d5
  • HY-163313S
    Tyk2-IN-19-d6 3018160-65-8 98%
    Tyk2-IN-19-d6 (compound 15) is the deuterium labeled Tyk2-IN-19 (HY-163313).
    Tyk2-IN-19-d6
  • HY-163581A
    HBV/HDV-IN-4 hydrochloride 3034059-40-7 98%
    HBV/HDV-IN-4 hydrochloride (Compd 4) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-4 hydrochloride
  • HY-16561S1
    Resveratrol-13C6 98%
    Resveratrol-13C6 is the 13C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
    Resveratrol-13C6
  • HY-167845S
    Exemestane-19-d3
    Exemestane-19-d3 is the deuterium labeled LD03-DEX (HY-167845). LD03-DEX is a precursor compound of dexamethasone (HY-14648) with immunosuppressive activity.
    Exemestane-19-d3
  • HY-167855S
    1’-Epi Gemcitabine hydrochloride-13C,15N2
    1’-Epi Gemcitabine hydrochloride-13C,15N2 is the 13C- and 15N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model.
    1’-Epi Gemcitabine hydrochloride-13C,15N2
  • HY-167926S
    Mycophenolic Acid-d3 beta-D-Glucuronide
    Mycophenolic Acid-d3 beta-D-Glucuronide is the deuterium labeled 3-Bromo-4,5-dihydroxybenzoic acid methyl ester (HY-167926). 3-Bromo-4,5-dihydroxybenzoic acid methyl ester is a marine-derived natural product known for its biological activity, specifically showcasing antioxidant properties and potential therapeutic applications against oxidative stress-related diseases.
    Mycophenolic Acid-d3 beta-D-Glucuronide
  • HY-16908AR
    Lefamulin acetate (Standard) 1350636-82-6
    Lefamulin (acetate) (Standard) is the analytical standard of Lefamulin (acetate). This product is intended for research and analytical applications. Lefamulin (BC-3781) acetate is an orally active antibiotic. Lefamulin acetate inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. Lefamulin acetate has anti-inflammatory activity. Lefamulin acetate can be used in the research of bacterial infections, such as bacterial pneumonia[1].
    Lefamulin acetate (Standard)
  • HY-169115A
    (Rac)-PD0299685 313651-02-4 98%
    (Rac)-PD0299685 is a Ca(2+) channel α2δ ligand that was investigated for relieving interstitial cystitis pain in a randomized, double-blind, placebo-controlled phase IIa study. (Rac)-PD0299685 demonstrated a clinically significant reduction in daily worst pain severity scores at the 60 mg dose compared to placebo. (Rac)-PD0299685 is also a potent voltage-dependent calcium channel inhibitor for the study of retina-related diseases.
    (Rac)-PD0299685
  • HY-169984S
    Tyk2-IN-22-d3 1771691-32-7 98%
    Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, JAK1, and JAK3 with IC50s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation.
    Tyk2-IN-22-d3
  • HY-169986S
    TyK2-IN-21-d3 2583719-08-6 98%
    TyK2-IN-21-d3 (Compound 3c) is the orally active prodrug of the tyrosine kinase 2. TyK2-IN-21-d3 exhibits good chemical stability in aqueous system under different pHs. TyK2-IN-21-d3 alleviates the effect of gastric acid changes on drug absorption and improve the drug bioavailability in rat model.
    TyK2-IN-21-d3
  • HY-17021S1
    Esomeprazole-d3 98%
    Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole-d3
  • HY-17021S2
    Esomeprazole-d3 potassium 98%
    Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole-d3 potassium
Cat. No. Product Name / Synonyms Application Reactivity